Day-one subcutaneous Leqembi Iqlik, an amyloid-targeting antibody drug for early Alzheimer's, lets eligible patients start treatment at home in 2026 without IV infusions. For family caregivers, the delivery method changed while eligibility, expected benefit, and safety monitoring did not.
Eisai and Biogen announced in the FDA approval notice that the FDA approved the home-start dose on July 13, 2026. Managed Healthcare Executive reported in its launch report that the initiation autoinjectors reached U.S. specialty pharmacy in late August 2026.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does home initiation work?
- Who still qualifies?
- Why are MRI checks still required?
- What was not proven separately?
- What should caregivers ask and arrange?
How does home initiation work?
The starting regimen is 500 mg once weekly, given as two back-to-back 250-mg autoinjector shots. Eisai and Biogen stated in the dosing announcement that each injection takes about 15 seconds. A patient or trained caregiver gives the shots at home from the first week.
Families do not have to choose home injections; clinic IV infusions remain available. The main tradeoff is convenience and caregiver tasks versus regular infusion-center visits. Managed Healthcare Executive lists wholesale cost at $385 per autoinjector, or $770 each initiation week.
Who still qualifies?
Eligibility did not expand with the new delivery route. FDA labeling summarized by Drug Topics limits treatment to adults with mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid pathology.
Check these points with the diagnosing clinician: If any point is missing, home Leqembi is not an option at that visit. A memory-clinic workup must confirm both stage and amyloid before specialty pharmacy can dispense the initiation dose.
- adult with mild cognitive impairment or mild dementia thought due to Alzheimer's
- amyloid buildup confirmed by the test required for prescribing
- current stage matches the approved early-Alzheimer's use
Why are MRI checks still required?
Home dosing does not remove the risk of amyloid-related imaging abnormalities, called ARIA. The FDA said in its safety communication that patients need an additional earlier MRI before the 3rd infusion to catch edema sooner.
Expect travel for brain scans even after infusions stop. Ask the prescriber for the full MRI timetable and where results go after hours. Do not skip a scan because injections feel routine.
What was not proven separately?
The home-start dose did not go through its own large outcomes trial. Drug Topics reports the FDA decision bridged IV CLARITY AD results with pharmacokinetic equivalence and similar amyloid-plaque reduction.
That means benefit expectations still rest on IV trial results, not separate home-shot outcomes. Caregivers should weigh convenience against that indirect evidence and the unchanged safety burden. The delivery is new; the disease effect and monitoring load are not.
What should caregivers ask and arrange?
Use the first prescribing visit to settle logistics: Leave with written training, the MRI schedule, and a 24-hour contact for concerns. Confirm specialty-pharmacy delivery dates before the first home-dose week.
- home shots versus clinic IV, and who will give injections
- hands-on training, supply handling, and the missed-dose plan
- MRI dates, transportation, and payment steps through specialty pharmacy
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: What Is Established and What Remains Uncertain for Primary Care Patients
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Is Established and What Remains Uncertain for Primary Care Patients
- How the CDPAP Switch to a Single Fiscal Intermediary Affects Family Caregivers
